Advertisement

Vertex Pharmaceuticals (Nasdaq:VRTX) has announced additional positive results for its experimental therapy for Cystic Fibrosis.

A Phase 3 Study of the drug candidate, called VX-770, in children between 6 and 11 with a specific type of CF, found lung function improved by 17.4 percent. This is a 24-week analysis of an ongoing study, which focuses on a sub-set of patients with a certain gene mutation.

SOURCE

Advertisement
Advertisement